Prazosin

Generic Name
Prazosin
Brand Names
Minipress, Minizide
Drug Type
Small Molecule
Chemical Formula
C19H21N5O4
CAS Number
19216-56-9
Unique Ingredient Identifier
XM03YJ541D
Background

Prazosin is a drug used to treat hypertension. Prazosin is marketed by Pfizer and was initially approved by the FDA in 1988. It belongs to the class of drugs known as alpha-1 antagonists.

Recently, many studies have evaluated the benefits of this drug in controlling the symptoms of post-traumatic stress disorder (PTSD) and associated nightmares.

Indication

This drug is indicated for the treatment of hypertension (high blood pressure). Prazosin can be given alone or given with other blood pressure-lowering drugs, including diuretics or beta-adrenergic blocking agents .
...

Associated Conditions
Agitation, Benign Prostatic Hyperplasia (BPH), Hypertension, Raynaud's Phenomenon, Disturbed sleep/nightmares
Associated Therapies
-

Efficacy of Sleep Interventions for Posttraumatic Stress Disorder (PTSD)

First Posted Date
2006-10-29
Last Posted Date
2016-10-24
Lead Sponsor
University of Pittsburgh
Target Recruit Count
50
Registration Number
NCT00393874
Locations
🇺🇸

Western Phychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Prazosin vs. Paroxetine in Combat Stress Symptoms in OIF/OEF Returnees

First Posted Date
2005-12-05
Last Posted Date
2009-12-03
Lead Sponsor
US Department of Veterans Affairs
Target Recruit Count
210
Registration Number
NCT00261729
Locations
🇺🇸

VA Puget Sound Health Care System, Seattle, Seattle, Washington, United States

Prazosin for ETOH or Cocaine Craving

Not Applicable
Terminated
Conditions
Interventions
First Posted Date
2005-10-17
Last Posted Date
2018-08-31
Lead Sponsor
US Department of Veterans Affairs
Target Recruit Count
8
Registration Number
NCT00240227
Locations
🇺🇸

VA Puget Sound Health Care System, Seattle, Washington, United States

Prazosin vs Paroxetine in Combat Stress-Related Post-Traumatic Stress Disorder (PTSD) Nightmares & Sleep Disturbance

First Posted Date
2005-09-20
Last Posted Date
2018-07-10
Lead Sponsor
Seattle Institute for Biomedical and Clinical Research
Target Recruit Count
59
Registration Number
NCT00202449
Locations
🇺🇸

Madigan Army Medical Center, Fort Lewis, Washington, United States

🇺🇸

Walter Reed Army Medical Center, Washington, District of Columbia, United States

Prazosin for Treating Noncombat Trauma Post-Traumatic Stress Disorder

First Posted Date
2005-09-16
Last Posted Date
2018-06-14
Lead Sponsor
Seattle Institute for Biomedical and Clinical Research
Target Recruit Count
20
Registration Number
NCT00183430
Locations
🇺🇸

VA Puget Sound Health Care System, Seattle, Washington, United States

Feasibility Study: The Effect of Prazosin for Nighttime Symptoms of Civilian PTSD

Not Applicable
Conditions
First Posted Date
2005-09-15
Last Posted Date
2006-09-11
Lead Sponsor
Rainier Associates
Target Recruit Count
20
Registration Number
NCT00174551
Locations
🇺🇸

Fletcher B. Taylor, Tacoma, Washington, United States

Prazosin Alcohol Dependence IVR Study

Phase 4
Completed
Conditions
Interventions
First Posted Date
2005-09-14
Last Posted Date
2008-02-15
Lead Sponsor
University of Washington
Target Recruit Count
23
Registration Number
NCT00167687
Locations
🇺🇸

VA Puget Sound Health Care System, Seattle, Washington, United States

Alzheimer's in Long-Term Care--Treatment for Agitation

First Posted Date
2005-09-12
Last Posted Date
2012-08-02
Lead Sponsor
University of Washington
Target Recruit Count
24
Registration Number
NCT00161473
Locations
🇺🇸

Veterans Affairs Puget Sound Health Care System, Seattle, Washington, United States

Prazosin Treatment for Combat Trauma PTSD (Post-Traumatic Stress Disorder) Nightmares and Sleep Disturbance

Phase 4
Completed
Conditions
First Posted Date
2005-04-15
Last Posted Date
2009-01-21
Lead Sponsor
US Department of Veterans Affairs
Registration Number
NCT00108420
Locations
🇺🇸

VA Puget Sound Health Care System, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath